Rigel Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

FAIR VALUE (Tables)

FAIR VALUE (Tables)

12 Months Ended

Dec. 31, 2020

Schedule of financial assets measured at fair value on a recurring basis

Financial assets measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations (in thousands):


	Assets at Fair Value as of December 31, 2020
	Level 1		Level 2		Level 3		Total
Money market funds	$	19,487	$	—	$	—	$	19,487
U.S. treasury bills		—		10,034		—		10,034
Government-sponsored enterprise securities		—		4,920		—		4,920
Corporate bonds and commercial paper		—		20,898		—		20,898
Total	$	19,487	$	35,852	$	—	$	55,339


	Assets at Fair Value as of December 31, 2019
	Level 1		Level 2		Level 3		Total
Money market funds	$	7,457	$	—	$	—	$	7,457
U.S. treasury bills		—		12,539		—		12,539
Government-sponsored enterprise securities		—		19,017		—		19,017
Corporate bonds and commercial paper		—		55,694		—		55,694
Total	$	7,457	$	87,250	$	—	$	94,707